Atypical Chronic Myeloid Leukemia in Two Pediatric Patients

Pediatric Blood and Cancer

Volumn 63, Issue 1, 2016, Pages 156-159

  Freedman, Jason L ^a,b   Desai, Ami V ^a,b   Bailey, L Charles ^a,b   Aplenc, Richard ^a,b   Burnworth, Bettina ^c   Zehentner, Barbara K ^c   Teachey, David T ^a,b   Wertheim, Gerald ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HEMATOLOGICS INC   (United States)

Author keywords

Atypical CML; BCR ABL1 negative; Leukemia; Myeloid; Pediatrics

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DECITABINE; ETOPOSIDE; HYDROXYUREA; RUXOLITINIB; THIOTEPA; UNCLASSIFIED DRUG; COLONY STIMULATING FACTOR RECEPTOR; CSF3R PROTEIN, HUMAN; PYRAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADOLESCENT; ANEMIA; ARTICLE; ATYPICAL CHRONIC MYELOID LEUKEMIA; BASOPHILIA; BONE MARROW EXAMINATION; BONE PAIN; CANCER RECURRENCE; CASE REPORT; CENTRAL NERVOUS SYSTEM LEUKEMIA; CEREBROSPINAL FLUID CYTOLOGY; CHILD; CSF3R GENE; CYTOGENETICS; DRUG RESPONSE; DYSPLASIA; EPIDURAL HEMATOMA; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE MUTATION; GRAFT REJECTION; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERPLASIA; KARYOTYPE; LABORATORY TEST; LEUKOCYTE COUNT; MOLECULAR DIAGNOSTICS; MONOCYTOSIS; MONOSOMY; MUTATIONAL ANALYSIS; NAUSEA; NEUTROPHILIA; OUTCOME ASSESSMENT; PALLOR; PARALYSIS; PRIORITY JOURNAL; SCHOOL CHILD; SKIN BRUISING; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING; WHOLE BODY RADIATION; GENETICS; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; MUTATION;

ADOLESCENT; CHILD; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; MUTATION; PYRAZOLES; RECEPTORS, COLONY-STIMULATING FACTOR;

EID: 84951567014     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25694     Document Type: Article

References (18)

1. Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi A. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 2014; 123:2645-2651.
2. Orazi A, Germing U. The myelodysplastic/myeloproliferative neoplasms: Myeloproliferative diseases with dysplastic features. Leukemia 2008; 22:1308-1319.
3. Langabeer SE, McCarron SL, Haslam K, O'Donovan MT, Conneally E. The CSF3R T618I mutation as a disease-specific marker of atypical CML post allo-SCT. Bone Marrow Transpl 2014; 49:843-844.
4. Gotlib J, Maxson JE, George TI, Tyner JW. The new genetics of chronic neutrophilic leukemia and atypical CML: Implications for diagnosis and treatment. Blood 2013; 122:1707-1711.
5. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardinam JW. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008.
6. Muramatsu H, Makishima H, Maciejewski JP. Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: Novel pathogenetic lesions. Semin Oncol 2012; 39:67-73.
7. Hernández JM, del Cañizo MC, Cuneo A, García JL, Gutiérrez NC, González M, Castoldi G, San Miguel JF. Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol 2000; 11:441-444.
8. Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, Antolini L, Mologni L, Donadoni C, Papaemmanuil E, Schnittger S, Kim DW, Boultwood J, Rossi F, Gaipa G, De Martini GP, di Celle PF, Jang HG, Fantin V, Bignell GR, Magistroni V, Haferlach T, Pogliani EM, Campbell PJ, Chase AJ, Tapper WJ, Cross NC, Gambacorti-Passerini C. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013; 45:18-24.
9. Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 2013; 368:1781-1790.
10. Murayama H, Matsushita H, Ando K. Atypical chronic myeloid leukemia harboring NUP98-HOXA9. Int J Hematol 2013; 98:143-144.
11. Fleischman AG, Maxson JE, Luty SB, Agarwal A, Royer LR, Abel ML, MacManiman JD, Loriaux ML, Druker BJ, Tyner JW. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood 2013; 122:3628-3631.
12. Loh ML, Tasian SK, Rabin KR, Brown P, Magoon D, Reid JM, Chen X, Ahern CH, Weigel BJ, Blaney SM. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL 1011). Pediatr Blood Cancer 2015. doi: 10.1002/pbc.25575
13. Vignal CV, Lourenco DM, Noguti MA, Chauffaille Mde L, Kerbauy J. Hemorrhagic and thrombotic complications in patients with myeloproliferative diseases. Sao Paulo Med J 1997; 115:1575-1579.
14. Mohri H. Acquired von Willebrand disease and storage pool disease in chronic myelocytic leukemia. Am J Hematol 1986; 22:391-401.
15. Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64:1-12.
16. Wehmeier A, Daum I, Jamin H, Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann Hematol 1991; 63:101-106.
17. Gambacorti-Passerini CB, Donadoni C, Parmiani A, Pirola A, Redaelli S, Signore G, Piazza V, Malcovati L, Fontana D, Spinelli R, Magistroni V, Gaipa G, Peronaci M, Morotti A, Panuzzo C, Saglio G, Usala E, Kim DW, Rea D, Zervakis K, Viniou N, Symeonidis A, Becker H, Boultwood J, Campiotti L, Carrabba M, Elli E, Bignell GR, Papaemmanuil E, Campbell PJ, Cazzola M, Piazza R. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood 2015; 125:499-503.
18. Committee for Medicinal Products for Human Use Assessment Report: Jakavi (International non-proprietary name: Ruxolitinib). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002464/WC500133226.pdf. Published: April 19, 2012. Accessed: June 8, 2015.